New therapeutic options have emerged in the type 2 diabetes (T2DM) management paradigm that improve hyperglycemic control while decreasing cardiovascular risk. Watch this expert-led 90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and the resultant practical applications for patient care. Participants in this program will also receive expert advice on using ADA and AACE/ACE guidelines appropriately as well as other strategic insights to improve care for their patients with T2DM and cardiovascular risk. 

Learning Objectives

  • Describe the important inter-relationship between diabetes and cardiovascular risk
  • Utilize the ADA and AACE/ACE guidelines to mitigate and manage cardiovascular risk better for patients with diabetes
  • Integrate antidiabetic agents with proven cardiovascular safety and efficacy into the management of patients with diabetes to minimize cardiovascular sequelae

Faculty Disclosures

Christopher Cannon, MD

Contracted Research for Amgen, Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Takeda Pharmaceuticals U.S.A, Inc. Consulting Fees for Alnylam Pharmaceuticals Inc.; Amarin Pharma Inc.; Amgen, Inc.; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eisai, Inc.; GlaxoSmithKline; Kowa Pharmaceuticals, Inc., Lipimetix Development Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US; and Takeda Pharmaceuticals U.S.A, Inc. 

Yehuda Handelsman, MD, FACP, FNLA, MACE

Advisory Board for Amarin Pharma Inc.; Amgen, Inc., AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eisai Co.; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi US. Contracted Research for Amgen, Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Grifols; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US. Speaker’s Bureau for Amarin Pharma Inc.; Amgen, Inc.; AstraZeneca; Boehringer Ingelheim and Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi US. 

Charles Vega, MD, FAAFP

No financial relationships to disclose. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

pmiCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

pmiCME is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This program has been approved for 1.50 contact hour of continuing education, including 0.90 of pharmacology. 

Commercial Supporter

Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

Education Partner


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.